,2 Since the initial discovery of the ALK fusion oncogene driver in lung cancer in 2007, the development of numerous ALK tyrosine kinase inhibitors (TKIs) has transformed the treatment paradigm for patients diagnosed with advanced or metastatic ALK fusion-positive (ALK+) NSCLC, resulting in substantially improved outcomes and prognoses for patients.2 The gene discussed is ALK; the disease is non-small cell lung carcinoma.